secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001193125-24-154729
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya gets $3.85M from Dr. Reddy's for COYA 302 Phase 2 trial; first $6M royalties waived
--------------------------------------------------------------------------------

- Dr. Reddy's makes $3.85M one-time payment to Coya for funding first Phase 2 trial of COYA 302 in ALS.
- Dr. Reddy's has no obligation to pay the first $6M in royalties otherwise due under the DRL Development Agreement.
- Amendment effective June 4, 2024; payment due within 5 business days of Coya's invoice.
- Funds must be used solely for the Phase 2 trial in the U.S. as per the Development Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524154729/0001193125-24-154729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524154729/d838051d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-154729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer